

## 2023 OPA Annual Conference Learning Objectives

**ACPE #0129-0000-23-027-L99-P**            **0.1 CEU**

**ACPE #0129-0000-23-027-H99-P**            **0.1 CEU**

### **Pharmacists' Well-being & Resilience: Using the Well-being Index for Pharmacy Personnel**

*Brigid K. Groves, PharmD, MS*

At the completion of this activity, the participant will be able to:

1. define occupational burnout and its impact on health care and pharmacist well-being;
2. explain how the Well-being Index for Pharmacy Personnel (WBI) can be used to assess and monitor practitioner well-being and understand the national distress percent trends; and
3. discuss next steps in addressing environment contributors to pharmacists' burnout.

**ACPE #0129-0000-23-028-L05-P**            **0.1 CEU**

**ACPE #0129-0000-23-028-H05-P**            **0.1 CEU**

### **Medication Safety Vulnerabilities Within the Medication Use System**

*Shelly Morvay, PharmD, CPPS and Maria Sellas Wcislo, PharmD, BCPPS*

At the completion of this activity, the participant will be able to:

1. distinguish between high and low leverage safety strategies for improving the medication use system;
2. identify opportunities for learning from medication safety risks that are reported by other pharmacies;
3. discuss medication vulnerabilities in the ambulatory setting; and
4. identify opportunities to proactively mitigate risk in the medication use system.

**ACPE #0129-0000-23-029-L01-P**            **0.1 CEU**

**ACPE #0129-0000-23-029-H01-P**            **0.1 CEU**

### **Utilization of Continuous Glucose Monitors in Pharmacy Practice**

*Suzanne Higginbotham, PharmD, BCACP*

At the completion of this activity, the participant will be able to:

1. compare continuous glucose monitors currently available to patients with diabetes;
2. identify emerging continuous glucose monitor technology; and
3. apply continuous glucose monitor data and its use in treatment decisions.

**ACPE #0129-0000-23-030-L04-P**            **0.1 CEU**

**ACPE #0129-0000-23-030-H04-P**            **0.1 CEU**

### **Billing as a Pharmacist Provider: What You Need to Know about Codes**

*Stuart Beatty, PharmD, BCACP, FAPhA*

At the completion of this activity, the participant will be able to:

1. recognize which codes pharmacists can use for pharmacist provider status with Ohio Medicaid patients; and
2. discuss requirements needed for each billing code pharmacists can use for Ohio Medicaid patients.

**ACPE #0129-0000-23-031-L01-P**            **0.1 CEU**

**ACPE #0129-0000-23-031-H01-P**            **0.1 CEU**

### **How to Get Your ZZZ's: Pharmacologic Treatment Options for Insomnia**

*Kaitlin Kuznacic, PharmD*

At the completion of this activity, the participant will be able to:

1. identify causes and symptoms of insomnia;
2. compare and contrast pharmacologic and non-pharmacologic treatments for insomnia; and
3. examine a therapeutic treatment plan for insomnia based on patient specific factors.

**ACPE #0129-0000-23-032-L04-P 0.1 CEU**

**ACPE #0129-0000-23-032-H04-P 0.1 CEU**

**Social Determinants of Health: Our Next Public Health Challenge**

*Jamie Carmichael, MPA and Myriam Shaw Ojeda, R.Ph., PharmD*

At the completion of this activity, the participant will be able to:

1. define social determinants of health (SDoH) in the context of Ohio's biggest healthcare challenges;
2. explain current disparities and trends in SDoH in Ohio; and
3. outline practical ways pharmacists and student pharmacists can incorporate SDoH into patient care.

**ACPE #0129-0000-23-033-L99-P 0.1 CEU**

**ACPE #0129-0000-23-033-H99-P 0.1 CEU**

**The Biotech Industry: New Opportunities for Pharmacists**

*Facilitator: Marc A. Sweeney, PharmD, BCMAS; Panelists: Chris Antypas, PharmD; Harry Benson; and Scott Roberts*

At the completion of this activity, the participant will be able to:

1. describe the biotech industry's history and evolution;
2. discuss opportunities for pharmacists and pharmacy technicians within the biotech industry; and
3. list specific skills needed to meet the evolving needs of the biotech industry.

**ACPE #0129-0000-23-034-L01-P 0.1 CEU**

**ACPE #0129-0000-23-034-H01-P 0.1 CEU**

**Evolving Oral Cancer Therapies - Focus on Crowded Spaces**

*Marlo Blazer, PharmD, BCOP*

At the completion of this activity, the participant will be able to:

1. discuss the National Comprehensive Cancer Network (NCCN) recommendations for use of agents in the treatment paradigm of patients with advanced or metastatic breast cancer and non-small cell lung cancer (NSCLC);
2. differentiate between sub-populations that were evaluated in each of the hallmark trials with more than 1 agent indicated;
3. recognize the difference in pharmacokinetics, toxicity profiles, and management strategies of these populations; and
4. apply, based on evidence presented, a patient-tailored approach to the use of these agents.

**ACPE #0129-0000-23-035-L99-P 0.1 CEU**

**ACPE #0129-0000-23-035-H99-P 0.1 CEU**

**Ohio Research Forum 2023**

*Moderator: Aleda Chen, PharmD, PhD, FAPhA*

At the completion of this activity, the participant will be able to:

1. describe research projects being conducted by pharmacists, student pharmacists and faculty in Ohio; and
2. describe the impact these research projects have on the practice of pharmacy, economic/social/administrative areas within the profession and/or pharmacy education.

**ACPE #0129-0000-23-036-L05-P 0.1 CEU**

**ACPE #0129-0000-23-036-H05-P 0.1 CEU**

**Generation Rx Everyday: Incorporating Medication Safety Messaging into Your Daily Practice**

*Kelsey K. Schmuhl, PharmD, BCACP; Ruth Emptage, PharmD, BCGP; and Brittany Sandidge Lovatt, MBA*

At the completion of this activity, the participant will be able to:

1. discuss Generation Rx and the development of the Generation Rx Ambassador training program;
2. describe the adaptation of Generation Rx key messages to meet the needs of veterinary and nursing professionals;
3. review strategies to incorporate medication safety messaging into everyday pharmacy practice; and

4. identify opportunities to teach medication safety principles to students on experiential rotations through case-based scenarios.

**ACPE #0129-0000-23-037-L01-P**      **0.1 CEU**    **Note: live only**

**2023 OTC and Self-Care Challenge**

*Moderators: Kristine Cline, PharmD, MS and Max Conrad, PharmD*

At the completion of this activity, the participant will be able to:

1. identify and explain aspects of the effective and safe practice of pharmacy self-care treatments;
2. describe at least two over-the-counter (OTC) and prescription medication interactions; and
3. list three OTC medications along with their use and key counseling points for pharmacists to provide to consumers.

**ACPE #0129-0000-23-038-L01-P**      **0.1 CEU**

**ACPE #0129-0000-23-038-H01-P**      **0.1 CEU**

**More Than Stress: A Pharmacist's Guide to Addressing Anxiety**

*Cory P. Coffey, PharmD, BCACP, BCPP*

At the completion of this activity, the participant will be able to:

1. recognize the signs and symptoms of generalized anxiety disorder (GAD);
2. review how to screen for GAD and interpret results; and
3. select an appropriate treatment and monitoring plan for GAD based on patient specific factors.

**ACPE #0129-0000-23-039-L03-P**      **0.15 CEU**

**ACPE #0129-0000-23-039-H03-P**      **0.15 CEU**

**So You Thought You Knew Ohio Pharmacy Law: A Case-Based Discussion**

*Donnie Sullivan, R.Ph., PhD*

At the completion of this activity, the participant will be able to:

1. interpret cases related to pharmacy practice laws and rules;
2. interpret cases related to dispensing and recordkeeping of controlled substances;
3. interpret cases related to new pharmacy practice laws; and
4. describe practice situations and cases that tend to confuse pharmacists.

**ACPE #0129-0000-23-040-L04-P**      **0.15 CEU**

**ACPE #0129-0000-23-040-H04-P**      **0.15 CEU**

**Ohio Innovative Practice Forum 2023**

*Moderators: Jennifer Rodis, PharmD, FAPhA, and Aleda Chen, PharmD, PhD, FAPhA*

At the completion of this activity, the participant will be able to:

1. describe innovative pharmacy practice models in Ohio;
2. explain how individual pharmacy practices and practitioners are expanding patient care services;
3. describe the successes and challenges of these programs including their financial viability and impact on outcome measures; and
4. apply these ideas, opportunities, and resources to enhance his/her own pharmacy practice.

**ACPE #0129-0000-23-041-L08-P**      **0.15 CEU**

**ACPE #0129-0000-23-041-H08-P**      **0.15 CEU**

**Better Together: Utilizing an Interprofessional Escape Room to Educate Health Professional Students about Opioid Use Disorder**

*Kelsey K. Schmuhl, PharmD and Jon E. Sprague, PhD*

At the completion of this activity, the participant will be able to:

1. describe Scientific Committee on Opioid Prevention and Education (SCOPE);
2. discuss findings of SCOPE survey of health professional schools;
3. describe the development of the educational course and interprofessional escape room;
4. summarize the findings from pilot offering of educational symposium; and

5. identify opportunities for expanding upon the educational symposium in the future.

**ACPE #0129-0000-23-042-L01-P 0.15 CEU**

**ACPE #0129-0000-23-042-H01-P 0.15 CEU**

**Don't Miss a Beat! Outpatient Cardiovascular Updates**

*Sarah Aldrich Renner, PharmD, BCACP, and Marilee Clemons, PharmD, BCACP*

At the completion of this activity, the participant will be able to:

1. discuss the consequences of cardiovascular disease as it relates to other comorbidities;
2. summarize pharmacotherapeutic approaches to improve morbidity and mortality in outpatients with cardiovascular disease or who are at high risk of cardiovascular disease; and
3. discuss important outpatient clinical perspectives related to medications used to treat those with known cardiovascular disease or those at high risk of cardiovascular disease.

**ACPE #0129-0000-23-043-L05-P 0.1 CEU**

**ACPE #0129-0000-23-043-H05-P 0.1 CEU**

**Safety in Numbers: How the Growing Older Adult Population Influences Medication Safety**

*Chad Worz, PharmD, BCGP, FASCP*

At the completion of this activity, the participant will be able to:

1. define the older adult population growth over the next 5 to 30 years;
2. discuss the dynamics of aging and its influence on medication use;
3. recognize simple approaches to medication management that improves safety for older adults; and
4. describe the critical role of the pharmacist in health care in the next 30 years.

**ACPE #0129-0000-23-044-L04-P 0.1 CEU**

**ACPE #0129-0000-23-044-H04-P 0.1 CEU**

**Community Pharmacy Practice Transformation: Implementing Provider Status Services**

*Alison Haas, PharmD, R.Ph. and Ryan Waldschmidt, PharmD, R.Ph.*

At the completion of this activity, the participant will be able to:

1. discuss practice transformation needed to implement new patient care services and existing resources to assist pharmacies on their journey;
2. review best practices and outcomes from the CPESN Ohio pilot;
3. discuss the potential return on investment of pharmacist-provided clinical services to Medicaid patients in Ohio; and
4. compare and contrast a service-based financial model to the current dispensing model.

**ACPE #0129-0000-23-045-L99-P 0.1 CEU**

**ACPE #0129-0000-23-045-H99-P 0.1 CEU**

**Farming for Health**

*Amy Sapola, PharmD, FAIHM, IFMCP*

At the completion of this activity, the participant will be able to:

1. explain the difference between conventional and organic agriculture;
2. explain the importance of soil health and how it relates to human health; and
3. recognize how a Functional Medicine approach is utilized for preventative wellness and to improve chronic disease management through prescribing food as medicine.

**ACPE #0129-0000-23-046-L99-P 0.1 CEU**

**ACPE #0129-0000-23-046-H99-P 0.1 CEU**

**2023 Legislative Update**

*Michelle Fitzgibbon and E. Michael Murphy, PharmD, MBA*

At the completion of this activity, the participant will be able to:

1. discuss current legislative and policy changes at both the state and federal level that will impact the practice of pharmacy;

2. explain how to effectively advocate for OPA supported legislative changes with state legislators and federal elected officials; and
3. identify issues on OPA's legislative agenda for 2023-24 and what they may mean for pharmacy practice.

**ACPE #0129-0000-23-047-L99-P 0.15 CEU**

**ACPE #0129-0000-23-047-H99-P 0.15 CEU**

### **Leading in Times of Trauma: Helping Frontline Heroes Cope with Burnout**

*Helen Sairany, PharmD, MBA, BCACP*

At the completion of this activity, the participant will be able to:

1. discuss the psychological impact of COVID-19 on pharmacists;
2. identify the multiple factors, including vicarious trauma, work-related conditions, and compassion fatigue that can lead to exhaustion and burnout among pharmacists; and
3. discuss effective strategies that can be employed by pharmacies and pharmacist staff to prevent burnout and ensure staff wellbeing.

**ACPE #0129-0000-23-048-L04-P 0.15 CEU**

**ACPE #0129-0000-23-048-H04-P 0.15 CEU**

### **Innovative Pharmacy Business Plan Competition 2023**

*Finalist teams TBD*

At the completion of this activity, the participant will be able to:

1. identify essential components of a business plan, including mission statement, description of business, loan request, marketing plan and financial reports;
2. explain the importance of effective visual aids and nonverbal communication during presentation of a business plan; and
3. recognize how enthusiasm, professionalism and completeness can impact the effectiveness of a business plan presentation.

**ACPE #0129-0000-23-049-L01-P 0.15 CEU**

**ACPE #0129-0000-23-049-H01-P 0.15 CEU**

### **Migraine: Pharmacists' Opportunities to Improve Care Via Evidenced-Based Treatments and New Medications**

*Richard Wenzel, PharmD, CPPS*

At the completion of this activity, the participant will be able to:

1. define migraine's presentation, diagnosis, and impact;
2. use algorithms and validated tools to assess whether an individual may have migraine, is appropriate for over-the-counter medications, or requires a referral;
3. recommend treatment goals and medications endorsed by evidence-based guidelines as well as the discontinuation of drugs that can exacerbate migraine;
4. describe the indications, dose/frequency, administration, and warnings and precautions of recently FDA-approved migraine medications; and
5. outline a treatment regimen given a patient case scenario.

**ACPE #0129-0000-23-050-L06-P 0.15 CEU**

**ACPE #0129-0000-23-050-H06-P 0.15 CEU**

### **Immunization Update 2023**

*Donald L. Bennett, R.Ph., MBA*

At the completion of this activity, the participant will be able to:

1. discuss the Centers for Disease Control and Prevention (CDC) identified trends in vaccine-preventable disease prevalence this past year;
2. describe the recent changes in recommendations from the CDC Advisory Committee on Immunization Practices with an emphasis on COVID-19 and pneumococcal vaccines;
3. discuss the impact of the 2022-2023 influenza season and review vaccine effectiveness factors; and

4. describe initiatives to improve vaccine hesitancy and increase immunization rates including examples of misinformation and disinformation.

**ACPE #0129-0000-23-051-L03-P**                      **0.1 CEU**

**ACPE #0129-0000-23-051-H03-P**                      **0.1 CEU**

**2023 Ohio Law Review**

*Sheri Zapadka, PharmD, R.Ph.*

At the completion of this activity, the participant will be able to:

1. identify recent changes in state and federal laws and rules which impact pharmacy practice in Ohio;
2. describe the effect of recent law and rule changes on the practice of pharmacy;
3. discuss implementation strategies for law and rule compliance; and
4. review relevant board notices and publications.

**ACPE #0129-0000-23-052-L99-P**                      **0.1 CEU**

**ACPE #0129-0000-23-052-H99-P**                      **0.1 CEU**

**Motivational Interviewing: Moving from Basic Understanding to Practical Application**

*Bethanne Brown, PharmD, BCACP*

At the completion of this activity, the participant will be able to:

1. explain the basic motivational interviewing skills needed to facilitate behavior change;
2. critically examine the 4-processes of motivational interviewing as part of a patient encounter; and
3. design a strategy to move a patient from sustain to change talk as part of the evoking process of motivational interviewing.

**ACPE #0129-0000-23-053-L08-P**                      **0.1 CEU**

**ACPE #0129-0000-23-053-H08-P**                      **0.1 CEU**

**Unmasking Opioid Use Disorder**

*Samuel Stitzel, PharmD, R.Ph., BCPS*

At the completion of this activity, the participant will be able to:

1. compare the opioid epidemic in Ohio to other states;
2. discuss how to minimize the stigma of opioid use disorder;
3. review current Medication Assisted Treatment law in Ohio;
4. identify barriers to access and challenges between prescribers and pharmacists; and
5. recognize opportunities to increase access to care including harm reduction strategies.

**ACPE #0129-0000-23-054-L07-P**                      **0.1 CEU**

**ACPE #0129-0000-23-054-H07-P**                      **0.1 CEU**

**USP <797> Terminal Sterilization**

*Ross A. Caputo, PhD*

At the completion of this activity, the participant will be able to:

1. describe the parameters of terminal sterilization using steam and radiation sterilization;
2. explain the requirement for validation,  $10^{-6}$  PNSU (Probability of a Non-Sterile Unit); and
3. define PNSU (Probability of a Non-Sterile Unit) based upon bioburden.

**ACPE #0129-0000-23-055-L01-P**                      **0.1 CEU**

**ACPE #0129-0000-23-055-H01-P**                      **0.1 CEU**

**PGx Marks the Spot - Clinical Applications and Implementation of Pharmacogenomics to Support Patient-Centered Care**

*Mark Zangardi, PharmD, MS, BCOP*

At the completion of this activity, the participant will be able to:

1. outline key elements of pharmacogenomics;
2. identify resources that support interpretation and application of pharmacogenomics information in patient care;
3. describe evidence-based uses of pharmacogenomics in current clinical practice; and

4. employ pharmacogenomics information when creating patient-specific medication plans.

**ACPE #0129-0000-23-056-L04-P 0.1 CEU**

**ACPE #0129-0000-23-056-H04-P 0.1 CEU**

**Bringing Clinical Services to Life in Your Pharmacy: Lessons Learned from the Front Lines**

*Facilitator: Stuart Beatty, PharmD, BCACP, FAPhA; Panelists: Rebecca Lahrman, PharmD, MS, BCACP; Barry Klein, MS, R.Ph.; and Andrea Kowalski, PharmD*

At the completion of this activity, the participant will be able to:

1. discuss the facilitators and barriers pharmacists have reported when initiating clinical services; and
2. identify best practices for service selection and implementation into your practice setting.

**ACPE #0129-0000-23-057-L08-P 0.1 CEU**

**ACPE #0129-0000-23-057-H08-P 0.1 CEU**

**Current Trends and Impact of Recreational Drug Use**

*Darby Bryce, PharmD and Tod J. Grimm, R.Ph., MBA, 340B ACE*

At the completion of this activity, the participant will be able to:

1. identify established and novel drugs of concern in the United States;
2. discuss current State and National data and trends;
3. review naloxone history and access;
4. review narcotic prescribing laws in Ohio;
5. compare safety and efficacy of buprenorphine to conventional opioid therapies; and
6. identify paths for pharmacists to mitigate repercussions of the opioid epidemic.

**ACPE #0129-0000-23-058-L01-P 0.1 CEU**

**ACPE #0129-0000-23-058-H01-P 0.1 CEU**

**New Drug Update 2023**

*Karen Kier, PhD, M.Sc., R.Ph.*

At the completion of this activity, the participant will be able to:

1. review the pharmacology and therapeutics of prescription medications released to the market within the past year;
2. state the indications and clinical applications of the medications presented, and how they compare to current therapies;
3. list the most common adverse effects, toxicities, and significant drug-drug and drug-food interactions reported; and
4. explain important patient/caregiver counseling information for these medications.

**ACPE #0129-0000-23-059-L04-P 0.1 CEU**

**ACPE #0129-0000-23-059-H04-P 0.1 CEU**

**The Pharmacist of the Future: Value Based Pharmacy Services Beyond MTM and Vaccines**

*Sue Paul, R.Ph.*

At the completion of this activity, the participant will be able to:

1. recognize the impact a pharmacist can make in chronic disease state management;
2. list the benefits of including a pharmacist directly on the health care team as well as on patients, providers, and pharmacists themselves;
3. discuss where a pharmacist can be embedded into practice; and
4. apply the concept of value-based care to case studies.

**ACPE #0129-0000-23-060-L01-P 0.1 CEU**

**ACPE #0129-0000-23-060-H01-P 0.1 CEU**

**Functional Medicine Approach to Anxiety and Depression**

*Melody Hartzler, PharmD, BCACP, BC-ADM*

At the completion of this activity, the participant will be able to:

1. discuss root-causes of anxiety and depression through the biopsychosocial-spiritual model of mental health;
2. describe the relationship between the gut microbiome and brain function (AKA the gut-brain axis);
3. recognize the relationship between anxiety and depression and other chronic conditions; and
4. discuss the pharmacist's role in addressing anxiety and depression including lab work-up and nutritional supplementation.

**ACPE #0129-0000-23-061-L04-P            0.1 CEU**

**ACPE #0129-0000-23-061-H04-P            0.1 CEU**

**The High Costs of PBM Savings**

*Antonio Ciaccia and Benjamin Link, PharmD*

At the completion of this activity, the participant will be able to:

1. recognize how the disconnect between average wholesale price (AWP) and the actual acquisition costs of medicines can enable arbitrage;
2. identify PBM revenue streams that can discourage them from working to lower the prices of medicines; and
3. explain how the Ohio Medicaid single PBM is disrupting the pharmacy benefits landscape.

**ACPE #0129-0000-23-062-L04-P            0.1 CEU**

**ACPE #0129-0000-23-062-H04-P            0.1 CEU**

**340B Drug Pricing Program Overview**

*Jangus Whitner, PharmD, MHA, BCACP, 340B ACE*

At the completion of this activity, the participant will be able to:

1. list basic principles of the 340B Drug Pricing Program;
2. outline covered entity eligibility requirements;
3. describe covered entity compliance cornerstones, including prevention of diversion and duplicate discounts; and
4. explain 340B pricing calculation and the role of manufacturers and wholesalers.

**ACPE #0129-0000-23-063-L01-P            0.1 CEU**

**ACPE #0129-0000-23-063-H01-P            0.1 CEU**

**RSV Trends, Treatments and Future Possibilities**

*Terry Laurila, MS, R.Ph., BCSCP*

At the completion of this activity, the participant will be able to:

1. explain the changes in respiratory syncytial virus (RSV) seasonality;
2. discuss how the investigational monoclonal antibodies differ from Palivizumab; and
3. define how an RSV Vaccine could fit into the RSV prophylactic treatment regimen.